Oncoinvent ASA Statistics
Total Valuation
Oncoinvent ASA has a market cap or net worth of NOK 144.66 million. The enterprise value is 75.49 million.
Market Cap | 144.66M |
Enterprise Value | 75.49M |
Important Dates
The last earnings date was Wednesday, August 27, 2025.
Earnings Date | Aug 27, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Oncoinvent ASA has 97.74 million shares outstanding. The number of shares has increased by 555.68% in one year.
Current Share Class | 97.74M |
Shares Outstanding | 97.74M |
Shares Change (YoY) | +555.68% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 11.80% |
Owned by Institutions (%) | 21.15% |
Float | 51.09M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 7.23 |
PB Ratio | 2.08 |
P/TBV Ratio | 2.08 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.71 |
EV / Sales | 3.78 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.88 |
Financial Position
The company has a current ratio of 2.61, with a Debt / Equity ratio of 0.09.
Current Ratio | 2.61 |
Quick Ratio | 2.61 |
Debt / Equity | 0.09 |
Debt / EBITDA | n/a |
Debt / FCF | -0.07 |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | -147.73% |
Revenue Per Employee | 555,444 |
Profits Per Employee | -2.96M |
Employee Count | 34 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 1.43 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 52.44 |
Average Volume (20 Days) | 67,472 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncoinvent ASA had revenue of NOK 20.00 million and -106.73 million in losses. Loss per share was -0.84.
Revenue | 20.00M |
Gross Profit | 20.00M |
Operating Income | -107.76M |
Pretax Income | -106.73M |
Net Income | -106.73M |
EBITDA | -98.87M |
EBIT | -107.76M |
Loss Per Share | -0.84 |
Balance Sheet
The company has 75.39 million in cash and 6.21 million in debt, giving a net cash position of 69.17 million or 0.71 per share.
Cash & Cash Equivalents | 75.39M |
Total Debt | 6.21M |
Net Cash | 69.17M |
Net Cash Per Share | 0.71 |
Equity (Book Value) | 69.46M |
Book Value Per Share | 0.71 |
Working Capital | 50.42M |
Cash Flow
In the last 12 months, operating cash flow was -83.80 million and capital expenditures -1.80 million, giving a free cash flow of -85.60 million.
Operating Cash Flow | -83.80M |
Capital Expenditures | -1.80M |
Free Cash Flow | -85.60M |
FCF Per Share | -0.88 |
Margins
Gross Margin | 100.00% |
Operating Margin | -538.89% |
Pretax Margin | -533.74% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Oncoinvent ASA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -555.68% |
Shareholder Yield | n/a |
Earnings Yield | -73.78% |
FCF Yield | -59.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Oncoinvent ASA has an Altman Z-Score of -8.25 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -8.25 |
Piotroski F-Score | 2 |